Sionna Therapeutics (NASDAQ:SION) Lowered to Strong Sell Rating by Wall Street Zen

by · The Cerbat Gem

Wall Street Zen lowered shares of Sionna Therapeutics (NASDAQ:SION – Free Report) from a sell rating to a strong sell rating in a research report released on Saturday.

Several other research analysts have also issued reports on the stock. JonesTrading lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 10th. Stifel Nicolaus reiterated a “hold” rating and set a $7.00 price objective on shares of Sionna Therapeutics in a research report on Monday, August 10th. Royal Bank Of Canada upgraded shares of Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 price objective for the company in a research report on Monday, August 10th. BTIG Research downgraded shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 10th. Finally, Lifesci Capital lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 10th. One investment analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $42.22.

Get Our Latest Analysis on SION

Sionna Therapeutics Stock Down 1.2%

Shares of NASDAQ:SION opened at $6.46 on Friday. The firm has a market cap of $292.06 million, a P/E ratio of -2.96 and a beta of 1.33. Sionna Therapeutics has a 12-month low of $4.01 and a 12-month high of $54.97. The business has a fifty day simple moving average of $39.18 and a 200 day simple moving average of $39.18.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.02). As a group, equities research analysts expect that Sionna Therapeutics will post -2.55 EPS for the current year.

Insider Activity

In related news, Director Peter A. Thompson sold 85,918 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director owned 2,469,959 shares in the company, valued at $110,802,360.74. This represents a 3.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the completion of the transaction, the director directly owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. The trade was a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 403,726 shares of company stock valued at $18,259,354. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Deutsche Bank AG boosted its holdings in Sionna Therapeutics by 4.5% during the 4th quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock worth $413,000 after acquiring an additional 433 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Sionna Therapeutics by 8.8% in the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after acquiring an additional 529 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Sionna Therapeutics by 6.6% in the fourth quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock valued at $352,000 after purchasing an additional 532 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Sionna Therapeutics by 35.2% during the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares in the last quarter. Finally, State of Wyoming bought a new position in shares of Sionna Therapeutics during the second quarter valued at about $35,000.

Sionna Therapeutics Company Profile

(Get Free Report)

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

Read More